Ozempic & Wegovy Cost in 2026: Insurance Coverage Guide

GLP-1 receptor agonists—Ozempic, Wegovy, Mounjaro, Zepbound—are the most talked-about drugs in America, with list prices that can exceed $1,350 per month. Whether you pay $25 or $1,350 comes down almost entirely to your insurance coverage and whether you can navigate the prior authorization process. BillKarma data shows GLP-1 prior auth denials increased 340% from 2023 to 2026, but 51% of appeals succeed. This guide shows you exactly how to get coverage, use manufacturer savings programs, and win a denial appeal.

1. GLP-1 drug price comparison

Four GLP-1 drugs dominate the market in 2026. Each has a different FDA-approved indication, dosing, and formulary status. Here is how their list prices and typical insurance costs compare:

The key distinction: diabetes-indicated drugs (Ozempic, Mounjaro) are covered by most commercial plans as standard medications. Obesity-indicated drugs (Wegovy, Zepbound) face far more restrictive coverage policies, even though the same active ingredient at a different dose is used for both purposes.

2. How insurance covers these drugs

Coverage depends on two factors: the FDA indication your doctor is prescribing for, and your plan’s formulary and obesity drug policy.

For Type 2 diabetes (Ozempic, Mounjaro): Most commercial plans cover these drugs, typically on Tier 3 or Tier 4 of the formulary. Expect a $50–$150 monthly copay or 20–40% coinsurance. Prior authorization is common and usually straightforward—your doctor provides the A1C level and diabetes diagnosis code (E11.x).

For obesity (Wegovy, Zepbound): Coverage has expanded but varies significantly. Typical plan requirements for coverage:

1. Documented BMI ≥30, OR BMI ≥27 with at least one weight-related condition (hypertension, obstructive sleep apnea, Type 2 diabetes, dyslipidemia, or cardiovascular disease)
2. Documentation of participation in a lifestyle modification program (behavioral therapy, diet counseling)
3. Prior authorization with physician justification letter
4. Some plans require step therapy—trying and failing an older, cheaper weight loss medication first (e.g., phentermine/topiramate)
5. Ongoing coverage often requires documented weight loss progress (5% body weight loss within 12–16 weeks)

Large employers have been the fastest adopters. A 2025 KFF survey found that 42% of large employers (1,000+ employees) cover obesity drugs, up from 25% in 2023. If your employer-sponsored plan doesn’t cover Wegovy today, it’s worth asking HR about the next plan year.

3. Navigating prior authorization

Prior authorization (PA) is required for virtually all GLP-1 drug coverage. The process typically takes 3–10 business days. Here is how to maximize your approval chances on the first submission:

1. Ensure your diagnosis codes are correct. For obesity drugs: E66.01 (morbid obesity), E66.09 (other obesity), or the specific weight-related comorbidity code. Your doctor’s coding matters enormously.
2. Document your BMI in the medical record at the current visit. Insurers often deny because the BMI isn’t clearly documented in the chart note the PA is based on.
3. Include comorbidity documentation. List every qualifying weight-related condition with its ICD-10 code: hypertension (I10), sleep apnea (G47.33), pre-diabetes (R73.09).
4. Document prior treatment attempts. Include dates of behavioral counseling, dietary program participation, or prior weight loss medication use. Even if your plan doesn’t technically require step therapy, showing you’ve tried other approaches strengthens the PA.
5. Have your doctor write a letter of medical necessity stating clinical rationale. A templated letter is far less effective than a specific, patient-tailored letter citing your patient’s chart data.

4. Medicare and Medicaid coverage

Medicare Part D historically prohibited coverage of weight loss medications under the Social Security Act. This has been a major barrier for older Americans seeking GLP-1 drugs for obesity.

Current Medicare status (2026):

• Ozempic and Mounjaro: covered under Part D for members with Type 2 diabetes diagnosis
• Wegovy: now covered under Part D for members with established cardiovascular disease (following the SELECT trial results). Not covered for obesity alone without CVD
• Zepbound: coverage for CVD indication is under review
• Some Medicare Advantage plans have added broader obesity drug coverage as an enhanced benefit—check your specific plan

The Treat and Reduce Obesity Act, which would require Medicare to cover obesity drugs broadly, has been introduced in multiple Congresses but has not passed as of 2026. Check your plan documents or call 1-800-MEDICARE for your specific coverage.

Medicaid: Coverage varies by state. As of 2026, approximately 30 states cover at least one GLP-1 drug for obesity under Medicaid. Check your state Medicaid formulary at your state’s Medicaid website.

5. Manufacturer savings programs

Both Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) offer savings programs for commercially insured patients who meet eligibility requirements. These are not available for Medicare or Medicaid beneficiaries.

Apply for these savings cards directly on the manufacturer’s website. Your pharmacist can also apply the savings card at the point of dispensing. Note: savings card eligibility and terms change frequently—verify current terms at the manufacturer’s website before relying on these figures.

6. Compound semaglutide: risks and legal status

During the 2022–2024 shortage of Ozempic and Wegovy, compound pharmacies legally produced semaglutide copies because FDA shortage rules permitted it. The FDA declared the shortage resolved in early 2025, making compounded semaglutide no longer eligible for legal compounding under 503A or 503B pharmacy rules.

Despite this, a gray market persists. Compounded semaglutide continues to be sold by some pharmacies and telehealth platforms. The risks are significant:

• No FDA oversight of potency, sterility, or dosing accuracy
• Multiple reports of serious adverse events from incorrectly dosed compound products
• FDA issued warning letters and took enforcement action against numerous compound pharmacies in 2025
• Telehealth platforms selling compound semaglutide may be operating illegally

If cost is driving you toward compound products, exhaust the legitimate options first: manufacturer patient assistance programs, GoodRx, appeal your insurance denial, and consider whether an older, cheaper GLP-1 drug (liraglutide/Victoza) might be covered by your plan.

7. GoodRx vs. insurance: which is cheaper?

For most commercially insured patients on a standard formulary, insurance beats GoodRx for GLP-1 drugs. But the calculation changes in a few scenarios:

• High-deductible plans early in the plan year: If you haven’t met your deductible and your plan’s negotiated rate is still $600+/month, a GoodRx price of $850 may not save much—but the manufacturer savings card might bring your cost to $25.
• Uninsured patients: GoodRx prices for Ozempic range from $800 to $950—better than list but still expensive. The manufacturer patient assistance program is usually better for income-qualifying patients.
• Denied coverage for obesity indication: While fighting your appeal, you may need to pay out of pocket. Use the manufacturer savings card if you’re commercially insured, or GoodRx as a fallback.

8. How to appeal a coverage denial

A GLP-1 denial is not the end. Follow these steps to build a strong appeal:

1. Get the denial reason in writing. Your insurer must provide the specific reason for denial, the clinical criteria applied, and instructions for appeal. Request this in writing within 24 hours of the denial.
2. Identify the exact gap. Common denial reasons: missing comorbidity documentation, step therapy not satisfied, BMI not documented, drug not on formulary for the billed indication. Each requires a different response.
3. Have your doctor write a targeted letter. The letter should address the specific denial reason with clinical data from your chart: current BMI, A1C, blood pressure, comorbidities, prior treatments tried.
4. Include peer-reviewed evidence. Cite the SURMOUNT-1 trial (Zepbound), STEP-1 trial (Wegovy), or SELECT cardiovascular outcomes trial. Insurers respond to clinical evidence in appeals.
5. File within the deadline. Internal appeals must typically be filed within 180 days of the denial date. Missing the deadline forfeits your appeal right.
6. Request external review if the internal appeal fails. All plans governed by the ACA must offer external independent review. An independent organization reviews your case—their decision is binding on the insurer.

Frequently asked questions

Sources

• FDA: Semaglutide Shortage Status Updates
• KFF: Coverage of GLP-1 Obesity Drugs by Employer Plans
• NEJM: STEP-1 Trial — Semaglutide for Obesity (Wegovy)
• NEJM: SELECT Trial — Semaglutide Cardiovascular Outcomes
• CMS: Medicare Part D Drug Coverage
• Novo Nordisk Patient Support Programs
• Eli Lilly: Lilly Cares Foundation Patient Assistance